Cancer drug combo tested for rare gene mutation – but trial stopped early

NCT ID NCT05523440

Terminated Disease control Sponsor: University of Oklahoma Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested two drugs, niraparib and bevacizumab, alone or together, in people with recurrent endometrial or ovarian cancer that has a specific gene change called ARID1A. The goal was to see if the drugs could shrink tumors. However, the trial was stopped early after enrolling only 9 participants, so the findings are very limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: niraparib (Zejula) and bevacizumab (Avastin)
What this could lead to: If successful, this could point toward a targeted treatment option for people with recurrent endometrial or ovarian cancer that has an ARID1A mutation.
What could go wrong: The trial was terminated early with only 9 participants, so results are very limited and may not be reliable. It is also a Phase 2 study, meaning it is still early and may not lead to a standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARID1A GENE MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial cancer endometrial carcinoma endometrium neoplasm ovarian cancer ovarian carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ARID1A GENE MUTATION RECURRENT ENDOMETRIAL CARCINOMA RECURRENT OVARIAN CARCINOMA

Contacts and locations

Locations

University of Oklahoma Health Sciences Center, Stephenson Cancer Center

Oklahoma City, Oklahoma, 73104, United States
University of Virginia Comprehensive Cancer Center

Charlottesville, Virginia, 22903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.